 Cardiología |
|
| |
A Randomized Placebo-controlled Trial of Low-Molecular-Weight Heparin in the Prevention of Restenosis Following Coronary Balloon Angioplasty
|
|
| ED Grassman1, F Leya1, B Lewis2, J Moran3, D Welzel4, J Fareed1 | | 1Loyola University Medical Center, 2Hines VA Medical Center, Maywood, IL, 3Midwest Heart Institute, Downer's Grove, IL, USA and 4University Regensburg, Germany | | Low-molecular-weight heparin (LMWH) has demonstrated reduced rates of restenosis following balloon angioplasty in animal models. The aim of this study was to evaluate the safety and efficacy of long-term LMWH treatment in the prevention of restenosis following percutaneous transluminal coronary angioplasty (PTCA). A total of 115 patients, with 156 lesions, were randomly assigned to 3 months of self-administered certoparin (80 mg s.c. b.i.d.) or placebo. Restenosis was defined as greater than 50% luminal diameter narrowing, measured by quantitative coronary angiography, on the 6-month angiogram. Of the 99 patients who completed the study, 25 in the placebo group and 15 in the LMWH group developed restenosis of the target lesion (P = 0.069). When all lesions were considered, 35 lesions in the placebo group developed restenosis compared with 19 in the LMWH group (P = 0.032). Conclusion: Certoparin shows a tendency to prevent restenosis following PTCA. A larger trial will be necessary to draw firmer conclusions.
|
|
|
|